Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Skin Prick Test to Evaluate Immunogenic Response of SILURCLOUD™ Fibrous Collagen Matrix in Healthy Volunteers
NCT07473674 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to evaluate whether the SILURCLOUD™ Fibrous Collagen Matrix causes an allergic skin response in healthy adult volunteers. The main question it aims to answer is: Does the SILURCLOUD™ Fibrous Collagen Matrix produce a measurable allergic reaction following a skin prick test? Participants will: Undergo a skin prick test on the inner forearm using the study product and control substances Remain at the clinic for evaluation of the skin response approximately 15 minutes and 6 hours after application Return to the clinic 24-48 hours later for a final skin assessment The study will include healthy adult volunteers, including participants with Fitzpatrick Skin Type VI, to provide additional safety information requested by the U.S. FDA.
Conditions Studied
Interventions
- DRUG Glycerosaline
- DEVICE Collagen Matrix Skin Prick Test Device
- DRUG Histamine
Study Locations (1)
Pennsylvania
- SerenaGroup Monroeville — Monroeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07473674
The ClinicalTrials.gov registry entry for NCT07473674 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SerenaGroup, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Healthy Adult appearing as the primary indexed condition, and to 3 interventions — of which Glycerosaline is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07473674 reports 1 study location spanning 1 distinct geographic area — top geographies include Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07473674 about?
NCT07473674 is a clinical study titled "Skin Prick Test to Evaluate Immunogenic Response of SILURCLOUD™ Fibrous Collagen Matrix in Healthy Volunteers". The goal of this clinical trial is to evaluate whether the SILURCLOUD™ Fibrous Collagen Matrix causes an allergic skin response in healthy adult volunteers. The main question it aims to answer is: Does the SILURCLOUD™ Fibrous Collagen Matrix produce a measurable allergic reaction following a skin p...
What is the current status of trial NCT07473674?
This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2026-02. Estimated completion is 2026-03.
What conditions does trial NCT07473674 study?
This clinical trial studies the following conditions: Healthy Adult. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07473674?
The interventions under investigation include: Glycerosaline (DRUG), Collagen Matrix Skin Prick Test Device (DEVICE), Histamine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07473674?
This trial is sponsored by SerenaGroup, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07473674 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.